Brokerages forecast that Inogen Inc (NASDAQ:INGN) will report $0.52 earnings per share (EPS) for the current quarter, according to Zacks. Six analysts have made estimates for Inogen’s earnings, with the lowest EPS estimate coming in at $0.48 and the highest estimate coming in at $0.58. Inogen posted earnings per share of $0.33 during the same quarter last year, which would suggest a positive year-over-year growth rate of 57.6%. The company is scheduled to report its next quarterly earnings report on Tuesday, November 6th.
According to Zacks, analysts expect that Inogen will report full year earnings of $2.07 per share for the current fiscal year, with EPS estimates ranging from $2.01 to $2.12. For the next year, analysts expect that the business will report earnings of $2.17 per share, with EPS estimates ranging from $1.97 to $2.27. Zacks Investment Research’s earnings per share averages are an average based on a survey of research firms that follow Inogen.
Inogen (NASDAQ:INGN) last issued its quarterly earnings results on Tuesday, August 7th. The medical technology company reported $0.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.44 by $0.21. Inogen had a return on equity of 16.51% and a net margin of 10.39%. The firm had revenue of $97.24 million for the quarter, compared to analyst estimates of $81.61 million.
NASDAQ:INGN traded up $5.70 during mid-day trading on Tuesday, reaching $258.66. The company’s stock had a trading volume of 232,400 shares, compared to its average volume of 193,425. Inogen has a twelve month low of $91.80 and a twelve month high of $287.79. The firm has a market cap of $5.44 billion, a price-to-earnings ratio of 197.45, a PEG ratio of 5.03 and a beta of 1.22.
In other news, Director Heath Lukatch sold 500 shares of Inogen stock in a transaction dated Friday, July 6th. The stock was sold at an average price of $193.66, for a total value of $96,830.00. Following the transaction, the director now directly owns 1,489 shares of the company’s stock, valued at approximately $288,359.74. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Scott Wilkinson sold 17,188 shares of Inogen stock in a transaction dated Wednesday, August 1st. The shares were sold at an average price of $200.16, for a total value of $3,440,350.08. Following the completion of the transaction, the insider now directly owns 41,664 shares in the company, valued at $8,339,466.24. The disclosure for this sale can be found here. Insiders sold a total of 106,308 shares of company stock worth $23,498,421 over the last ninety days. Corporate insiders own 5.29% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in INGN. Catalyst Capital Advisors LLC purchased a new stake in shares of Inogen during the 2nd quarter valued at about $112,000. Advisors Preferred LLC purchased a new stake in shares of Inogen during the 2nd quarter valued at about $176,000. Thompson Siegel & Walmsley LLC purchased a new stake in shares of Inogen during the 2nd quarter valued at about $186,000. Raymond James Financial Services Advisors Inc. purchased a new stake in shares of Inogen during the 2nd quarter valued at about $216,000. Finally, SG Americas Securities LLC purchased a new stake in shares of Inogen during the 1st quarter valued at about $178,000. 96.47% of the stock is currently owned by institutional investors and hedge funds.
Inogen Company Profile
Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. The company's oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
Featured Article: Outstanding Shares, Buying and Selling Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.